氧化分解白术挥发油与羟丙基-β-环糊精包合工艺的研究

Study on inclusion process of decomposed volatile oil from Atractylodes macrocephala with hydroxypropyl-β-cyclodextrin

目的优化氧化分解白术挥发油(decomposed volatile oil from Atractylodes macrocephala,DVOA)与羟丙基-β-环糊精(HP-β-CD)的包合工艺。方法采用冷冻干燥法制备包合物,荧光分光光度法评价制备工艺。以包合率和含油率为指标,采用正交试验法,考察HP-β-CD与DVOA质量比、包合温度和包合时间对包合的影响,筛选出最佳包合工艺条件。通过紫外-可见光谱(UV-vis)、荧光光谱(FL)和显微成像法表征包合物,并进行稳定性测试,同时利用气相色谱-质谱联用(GC-MS)技术对DVOA包合前后的化学成分进行分析。结果 DVOA与HP-β-CD形成了包合物,其最佳包合条件为HP-β-CD与DVOA质量比为10:1,包合温度30℃,包合时间2.0 h,平均包合率和含油率分别为73.32%和10.43%。包合前后DVOA的化学成分相同,包合过程只是对各组分的比例略有影响。结论以最佳工艺条件制备的DVOA-HP-β-CD包合物工艺合理、稳定可行,可为DVOA的抗肿瘤新药研发提供可靠的实验基础。

Objective To optimize the inclusion process of decomposed volatile oil from Atractylodes macrocephala（DVOA） with hydroxypropyl-β-cyclodextrin（HP-R-CD）.Methods The inclusion complex was prepared by the freeze drying method.The preparation process was evaluated using fluorescence spectrophotometry.The inclusion process conditions were screened by the orthogonal test,with the inclusion ratio and oil ratio as indexes,and mass ratio between HP-β-CD and DVOA,inclusion temperature and inclusion time as the impacting factors.The inclusion complex was characterized through ultraviolet-visible spectra（UV-vis）,fluorescence spectra（FL） and microscopic imaging,and the stability test was performed.Simultaneously,the chemical composition in DVOA before and after inclusion was analyzed by GC-MS technique.Results The DVOA and HP-β-CD had formed inclusion complex,the optimal inclusion conditions were as follows：The mass ratio of HP-β-CD to DVOA was 10：1,the inclusion temperature was 30 ℃,the inclusion time was 2.0 h,and the ratios of average inclusion and oil were 73.32%and 10.43%,respectively.The chemical composition of DVOA was consistent before and after inclusion,the inclusion just had the slight effects on proportion of each component.Conclusion The preparation process of DVOA/HP-β-CD inclusion complex under the optimal conditions is reasonable,stable,and feasible,and can provide the reliable experimental basis for the anti-tumor new drug research and development of DVOA.